Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.32 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.32 |
| ▸ | FDPS | P14324 | 1/20 | 0.32 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.32 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 2/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.31 |
| ▸ | CA12 | O43570 | 1/20 | 0.31 |
| ▸ | CA6 | P23280 | 1/20 | 0.31 |
| ▸ | CA7 | P43166 | 1/20 | 0.31 |
| ▸ | RECQL | P46063 | 1/20 | 0.31 |
| ▸ | CA9 | Q16790 | 1/20 | 0.31 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.31 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL817856 | 0.86 | NFKB1 (0.38) | LMNAFDPSPDE3AMEN1KMT2A | |
| SCHEMBL547205 | 0.86 | NFKB1 (0.38) | LMNAFDPSPDE3AMEN1KMT2A | |
| SCHEMBL83217 | 0.86 | — | — | |
| SCHEMBL817373 | 0.84 | — | — | |
| SCHEMBL22927051 | 0.84 | — | — | |
| SCHEMBL818369 | 0.83 | ALDH1A1 (0.41) | LMNAADRB3FDPSPDE4DPDE3A | |
| SCHEMBL1289364 | 0.83 | FDPS (0.40) | FDPSMEN1KMT2A | |
| Hydrochloric Acid SCHEMBL4672267 | 0.81 | KDM4E (0.30) | — | |
| SCHEMBL817593 | 0.80 | DNM1 (0.47) | LMNAFDPSMEN1KMT2ACA12 | |
| SCHEMBL8034089 | 0.80 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 237 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023181081-A1 | SURFACE ACTIVATION OF SILICONE | HASKOLI ISLANDS (IS) | 2023-09-28 | — | — | WO | claimed |
| EP-3452057-A1 | COMPOSITIONS FOR TREATING ACID-BASE DISORDERS | Tricida Inc. (US) | 2019-03-13 | — | — | EP | claimed |
| WO-2017193050-A1 | COMPOSITIONS FOR TREATING ACID-BASE DISORDERS | TRICIDA, INC. (US) | 2017-11-09 | — | — | WO | claimed |
| US-8003705-B2 | In situ formation of slowly biodegradable materials; reaction between precursors having electrophilic and nucleophilic functionality; enzymatic and hydrolysis resistance; controlled drug delivery agents, postoperative adhesion prevention, medical device coatings, wound dressings, surgical sealants; kits | INCEPT LLC (US) | 2011-08-23 | — | — | US | claimed |
| EP-2196193-A1 | Hydrogels suitable for use in polyp removal | Tyco Healthcare Group LP (US) | 2010-06-16 | — | — | EP | claimed |
| US-20090324721-A1 | Hydrogels Suitable For Use In Polyp Removal | TYCO HEALTHCARE GROUP LP | 2009-12-31 | — | — | US | claimed |
| US-20080260802-A1 | Biocompatible hydrogels made with small molecule precursors | OCULAR THERAPEUTIX, INC. | 2008-10-23 | — | — | US | claimed |
| EP-1503802-A2 | CONTROLLABLY DEGRADABLE POLYMERIC BIOMOLECULE OR DRUG CARRIER AND METHOD OF SYNTHESIZING SAID CARRIER | NITTO DENKO CORPORATION (JP) | 2005-02-09 | — | — | EP | claimed |
| WO-2003097107-A2 | CONTROLLABLY DEGRADABLE POLYMERIC BIOMOLECULE OR DRUG CARRIER AND METHOD OF SYNTHESIZING SAID CARRIER | NITTO DENKO CORPORATION (JP) | 2003-11-27 | — | — | WO | claimed |
| US-20260009177-A1 | INK SET, FLUID APPLYING APPARATUS, FLUID APPLYING METHOD, AND PRINTED PRODUCT | RICOH COMPANY, LTD. (JP) | 2026-01-08 | — | — | US | disclosed |
| US-20250360249-A1 | EMBOLIC COMPOSITIONS AND METHODS | INSTYLLA, INC. | 2025-11-27 | — | — | US | disclosed |
| US-12397087-B2 | Embolic compositions and methods | INCEPT, LLC (US) | 2025-08-26 | — | — | US | disclosed |
| US-12010996-B2 | Tris-substituted biguanide compounds and their uses | CHEN HWANG HSING (US) | 2024-06-18 | — | — | US | disclosed |
| WO-2024121160-A1 | REGULATOR(S) OF ENERGY HOMEOSTASIS-ENCODING RNA MOLECULE(S) WITH INCREASED TRANSLATION EFFICIENCY | ETHRIS GMBH (DE) | 2024-06-13 | — | — | WO | disclosed |
| EP-0714387-A1 | NEW BIS-NAPHTHALIMIDES FOR THE TREATMENT OF CANCER | BASF AKTIENGESELLSCHAFT (DE) | 1996-06-05 | — | — | EP | disclosed |
| WO-1995005365-A1 | NEW BIS-NAPHTHALIMIDES FOR THE TREATMENT OF CANCER | BASF AKTIENGESELLSCHAFT (DE) | 1995-02-23 | — | — | WO | disclosed |
| US-5373087-A | Contacting polyfunctional amine with unsaturated alkylating agent, reacting with polyfunctional compound to form polymer, contacting with halogen or hypohalous acid, crosslinking or raising pH to increase molecular weight | THE DOW CHEMICAL COMPANY (US) | 1994-12-13 | — | — | US | disclosed |
| US-5278255-A | Crosslinking | THE DOW CHEMICAL COMPANY (US) | 1994-01-11 | — | — | US | disclosed |
| EP-0471594-A2 | Unsaturated polyaminopolymers, derivatives thereof, paper containing the polyaminopolymers processes for making all three | THE DOW CHEMICAL COMPANY (US) | 1992-02-19 | — | — | EP | disclosed |
| EP-0365479-A2 | Curable epoxide resin compositions | CIBA-GEIGY AG (CH) | 1990-04-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12010996-B2 | Tris-substituted biguanide compounds and their uses | PUF60, KCNN1, XRCC6 | LMNA 3989/4885ADRB3 4209/4885FDPS 4417/4885 |
| US-20260009177-A1 | INK SET, FLUID APPLYING APPARATUS, FLUID APPLYING METHOD, AND PRINTED PRODUCT | SORD, MAPT, TARDBP | LMNA 1955/4885ADRB3 3888/4885FDPS 3907/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.